Compare Fubotv Inc (FUBO) vs Hims and Hers Health Inc (HIMS) Price & Performance

FUBO trades at $9.46, up 1.07% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion (Business Wire, 2026-08-05) and raised its full-year adjusted EBITDA target to $90–$100 million. Valuation ratios appear attractive with a P/S of 0.19 and P/B of 0.36, while recent earnings showed mixed results with two beats and one miss in the last four quarters.

The outlook is cautiously optimistic with analyst consensus pointing to significant upside to a $15.33 price target. Key opportunities include subscriber growth from live sports and advertising improvements, but risks persist from negative cash flows and high debt levels. Execution under new CEO Alisa Bowen and partnerships with Disney and NBCUniversal are critical for achieving profitability targets.

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.